Moderna, Inc. (MRNA) News
Filter MRNA News Items
MRNA News Results
|Loading, please wait...|
MRNA News Highlights
- MRNA's 30 day story count now stands at 25.
- Over the past 27 days, MRNA's stories per day has been in a clear uptrend, growing by about 0.73 per 3 days.
- BA, DRUG and PFE are the most mentioned tickers in articles about MRNA.
Latest MRNA News From Around the Web
Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.
Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.
The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.
In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches. Effective January 1, 2023, Juan Andres will step into a new role as President, Strategic Partnerships and Enterprise Expansion, and will focus on building out the organization to support the growing pipeline.
These Growth Stocks to Buy Before the Bull Market Returns are trading at historical lows and offer massive upside potential
Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from the prior day.
This was the case with high-profile biotech Moderna (NASDAQ: MRNA) on Wednesday. Moderna's positive news came from across the Atlantic Ocean, where the European Medicines Agency (EMA) accepted a conditional marketing authorization (CMA) application for the company's bivalent coronavirus booster vaccine. Moderna didn't hesitate to point out that the new booster has already been given the green light by the U.S. Food and Drug Administration (FDA) and a host of other jurisdictions, including Australia, Taiwan, and the U.K.
Data is still scarce on latest COVID-19 boosters